Consumer Health/OTC Healthcare industry and market research, statistics, market share

Filter Summary

Country Report

Analgesics in New Zealand

Analgesics current retail value growth of 1% in 2011 was lower than the review period average of 2%, partly as a result of decreasing acetaminophen sales. Acetaminophen accounted for 39% of analgesics current retail value sales in 2011. In addition ...

Mar 2012 | US$900| Add to cart | View details ›

Country Report

Cough, Cold and Allergy (Hay Fever) Remedies in New Zealand

During 2010, the Associate Minister of Health introduced the Misuse of Drugs Amendment Bill which reclassified pseudoephedrine and ephedrine as Class B2 controlled drugs. This followed an agreement by the cabinet in September 2009 to reclassify these...

Mar 2012 | US$900| Add to cart | View details ›

Country Report

Digestive Remedies in New Zealand

Digestive remedies is a mature area and thus only recorded moderate current retail value growth of 1% in 2011. Towards the latter end of the review period, consumers were extremely price conscious and this trend continued within digestive remedies ...

Mar 2012 | US$900| Add to cart | View details ›

Country Report

Medicated Skin Care in New Zealand

During 2010, Regulatory Reform Minister, Rodney Hide, introduced the Regulatory Responsibility Bill to review and remove hundreds of regulations that are considered to hinder business practice in New Zealand. With regard to medicated skin care, this ...

Mar 2012 | US$900| Add to cart | View details ›

Country Report

NRT Smoking Cessation Aids in New Zealand

NRT smoking cessation aids current retail value growth of 8% in 2011 was slightly higher than the review period average of 7%. One of the biggest changes to tobacco excise taxation over the review period occurred during 2010, when the government ...

Mar 2012 | US$900| Add to cart | View details ›

Country Report

Eye Care in New Zealand

Current retail value growth of 4% in 2011 was in-line with the review period average. While standard eye care is a mature area, allergy eye care is more dynamic.

Mar 2012 | US$900| Add to cart | View details ›

Country Report

Ear Care in New Zealand

Ear care current retail value growth of 1% in 2011 was lower than the review period average of 3%. Growth rates are declining within the area due to stagnation. There were no unique or significant growth drivers to boost value sales during the year.

Mar 2012 | US$900| Add to cart | View details ›

Country Report

Adult Mouth Care in New Zealand

Current retail value growth of 2% in 2011 was slightly lower than the review period average of 3% due to the impact of increasing maturity.

Mar 2012 | US$900| Add to cart | View details ›

Country Report

Calming and Sleeping in New Zealand

The 5% increase in current retail value sales in 2011 was in-line with the review period CAGR. Furthermore, growth in 2011 was similar to that from 2009 to 2010. This highlights increasing consumer demand for products that help to provide a good ...

Mar 2012 | US$900| Add to cart | View details ›

Country Report

Wound Care in New Zealand

Current retail value growth of 2% in 2011 was lower than the review period average of 3% due to the impact of increasing maturity. During 2011, there were no new innovations within the area. However, Elastoplast did launch one new product.

Mar 2012 | US$900| Add to cart | View details ›